Trial NCT04398134

View at ClinicalTrials.gov 
Org. Study IDs: ABI-H2158-201
Secondary IDs: 2019-004902-85

Last trial update was posted on 2022-09-15

MeSH Interventions

Entecavir

MeSH Conditions

Hepatitis Hepatitis A Hepatitis B Hepatitis B, Chronic Hepatitis, Chronic

Other Conditions

Chronic Hepatitis B

Stopping Reasons

Study stopped due to a safety signal of drug-induced liver injury in subjects receiving 2158

Limitations And Caveats

Study ABI-H2158-201 was terminated early due to alanine aminotransferase (ALT) elevations among study participants who received ABI-H2158 (and not among those who received PBO). Further details on these events are described in the results section below. In the absence of an alternative etiology for the ALT elevations, further clinical development of ABI-H2158 was terminated by the Sponsor.

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID